Sanofi

Kurt Swanson

Gary J Nabel

Chih-Jen Wei

Te-Hui Chou

Laura Nguyen

Pradeep K Dhal

Ronnie Rong Wei

Magnus Besev

Stefan Koester

Ram Dharanipragada

Heather Kamp

This disclosure relates to antigenic multimeric respiratory syncytial virus (RSV) G polypeptides for use in eliciting an immune response to RSV.

Antigenic multimeric respiratory syncytial virus polypeptides

This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.

Antigenic Epstein Barr virus polypeptides

Antigenic respiratory syncytial virus (RSV) polypeptides for use in eliciting antibodies against RSV are provided. Also provided are antigenic polypeptides comprising an RSV polypeptide and a ferritin protein.

Antigenic respiratory syncytial virus polypeptides

Antigenic epstein barr virus polypeptides

This disclosure relates to antigenic OspA polypeptides and their use in eliciting antibodies against OspA. Also disclosed are antigenic polypeptides comprising an OspA polypeptide and a ferritin protein.

Antigenic OspA polypeptides

Ferritin proteins comprising a mutation replacing a surface-exposed amino acid with a cysteine, an N- or C-terminal linker comprising a cysteine, and/or one or more immune-stimulatory moieties linked to the ferritin protein via a surface-exposed amino acid are disclosed. The ferritin proteins can further comprise a non-ferritin polypeptide and be antigenic, e.g., for use in eliciting antibodies against the non-ferritin polypeptide.

Growing community of inventors

Bridgewater, NJ, United States of America

Kurt Swanson